Melanotan-II Boosted Energy Expenditure and Fat Use More in Inherently Lean Rats
Background
Differences in intrinsic aerobic capacity are linked to metabolic health, with high-capacity individuals often being leaner and more resistant to metabolic disease. A key component of this is activity thermogenesis, the energy expended during physical activity. The central melanocortin system, particularly receptors in the ventromedial hypothalamus (VMH), is a powerful regulator of both energy expenditure and physical activity. It's known that activating these receptors can stimulate energy use. This study investigates whether an individual's inherent aerobic capacity and lean phenotype are associated with a heightened response to this central melanocortin stimulation, potentially explaining the underlying mechanisms that maintain their lean state.
Study Design
The study used two rat phenotypes: inherently lean high-capacity runners (HCR) and low-capacity runners (LCR). Researchers administered intra-VMH microinjections of Melanotan II (MTII), a mixed melanocortin receptor agonist, to both groups. They then measured and compared changes in total energy expenditure (EE), activity EE, respiratory exchange ratio (a measure of fuel source), muscle heat production, and norepinephrine turnover in skeletal muscle (an indicator of sympathetic nervous system activity). They also assessed muscle mRNA expression of specific energetic modulators.
Results
High-capacity runner (HCR) rats were significantly more responsive to VMH administration of Melanotan II. Following the injection, HCR rats showed greater increases in total energy expenditure (EE) and activity EE compared to LCR rats. This heightened response was linked to the sympathetic nervous system, as norepinephrine turnover was elevated in some skeletal muscle subgroups of HCR rats after MTII. The increased EE was fueled by fat, evidenced by a lower respiratory exchange ratio. Central melanocortin activation also altered skeletal muscle energetic modulators in a way that supported these metabolic changes. Interestingly, while HCR rats inherently had high muscle activity thermogenesis, it was the LCR rats who showed a limited increase in muscle thermogenesis during activity after MTII treatment.
Key Findings
- Intra-VMH Melanotan II significantly increased energy expenditure (EE) and activity EE more in high-capacity runner (HCR) rats than in low-capacity (LCR) rats.
- The enhanced EE in HCR rats was associated with increased use of fat as a fuel source, indicated by a lowered respiratory exchange ratio.
- MTII elevated sympathetic outflow to skeletal muscle, measured by norepinephrine turnover, particularly in the more responsive HCR rats.
- Central melanocortin activation altered skeletal muscle mRNA expression of energetic modulators consistent with elevated energy expenditure.
- MTII-induced modulation of muscle thermogenesis during activity was observed in LCR rats only, despite HCRs having higher baseline muscle activity thermogenesis.
Why It Matters
This research suggests that an individual's baseline metabolic phenotype and aerobic capacity can dramatically influence their response to central melanocortin stimulation. For users of melanocortin agonists like Melanotan II, this implies that those who are already lean and have a high capacity for physical activity may experience a more pronounced increase in energy expenditure and fat burning. This highlights a potential synergistic effect between inherent fitness and melanocortin pathway activation. The findings reinforce the idea that the central nervous system's control over peripheral tissues, like skeletal muscle via sympathetic outflow, is a critical driver of the metabolic effects of these peptides. It also suggests that protocols might be more effective in individuals with a higher baseline fitness level.
melanotan-ii
energy expenditure
fat loss
metabolism
animal study
neuroscience
